Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash to Debt 4.94
NVIV's Cash to Debt is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. NVIV: 4.94 )
NVIV' s 10-Year Cash to Debt Range
Min: 0.11   Max: No Debt
Current: 4.94

F-Score: 2
Z-Score: -0.74
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry
vs
history
ROE (%) -300.67
NVIV's ROE (%) is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. NVIV: -300.67 )
NVIV' s 10-Year ROE (%) Range
Min: -15000   Max: -30.97
Current: -300.67

-15000
-30.97
ROA (%) -226.70
NVIV's ROA (%) is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. NVIV: -226.70 )
NVIV' s 10-Year ROA (%) Range
Min: -9000   Max: 29.04
Current: -226.7

-9000
29.04
ROC (Joel Greenblatt) (%) -813.22
NVIV's ROC (Joel Greenblatt) (%) is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. NVIV: -813.22 )
NVIV' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -1665.19   Max: -552.72
Current: -813.22

-1665.19
-552.72
EBITDA Growth (%) 32.30
NVIV's EBITDA Growth (%) is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. NVIV: 32.30 )
NVIV' s 10-Year EBITDA Growth (%) Range
Min: 0   Max: 306.2
Current: 32.3

0
306.2
EPS Growth (%) 29.40
NVIV's EPS Growth (%) is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. NVIV: 29.40 )
NVIV' s 10-Year EPS Growth (%) Range
Min: 0   Max: 306.2
Current: 29.4

0
306.2
» NVIV's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Insider Trades

Latest Guru Trades with NVIV



No Insider Trades Found!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 8.50
NVIV's P/B is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. NVIV: 8.50 )
NVIV' s 10-Year P/B Range
Min: 0   Max: 13.5
Current: 8.5

0
13.5
EV-to-EBIT -4.24
NVIV's EV-to-EBIT is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. NVIV: -4.24 )
NVIV' s 10-Year EV-to-EBIT Range
Min: 0   Max: 0
Current: -4.24

Current Ratio 5.29
NVIV's Current Ratio is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. NVIV: 5.29 )
NVIV' s 10-Year Current Ratio Range
Min: 0.14   Max: 14.81
Current: 5.29

0.14
14.81
Quick Ratio 5.29
NVIV's Quick Ratio is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. NVIV: 5.29 )
NVIV' s 10-Year Quick Ratio Range
Min: 0.14   Max: 14.81
Current: 5.29

0.14
14.81

Valuation & Return

vs
industry
vs
history
Price/Net Cash 13.57
NVIV's Price/Net Cash is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. NVIV: 13.57 )
NVIV' s 10-Year Price/Net Cash Range
Min: 7.94   Max: 38.75
Current: 13.57

7.94
38.75
Price/Net Current Asset Value 13.57
NVIV's Price/Net Current Asset Value is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. NVIV: 13.57 )
NVIV' s 10-Year Price/Net Current Asset Value Range
Min: 7.94   Max: 38.75
Current: 13.57

7.94
38.75
Price/Tangible Book 8.64
NVIV's Price/Tangible Book is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. NVIV: 8.64 )
NVIV' s 10-Year Price/Tangible Book Range
Min: 6.5   Max: 19.38
Current: 8.64

6.5
19.38
Forward Rate of Return (Yacktman) -10.88
NVIV's Forward Rate of Return (Yacktman) is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. NVIV: -10.88 )
NVIV' s 10-Year Forward Rate of Return (Yacktman) Range
Min: 0   Max: 0
Current: -10.88

Business Description

Industry: »
Compare: » details
InVivo Therapeutics Holdings Corp. is a Nevada Corporation. The Company develops and commercializes technologies for the treatment of spinal cord injuries (SCI). It intends to create a new paradigm of care for SCI. Current treatments consist of a collection of approaches that only focus on symptoms of SCI. To date, it is not aware of any product on the market that addresses the underlying pathology of a SCI. Currently there are no successful spinal cord injury treatment options for SCI patients. InVivo takes a novel approach to SCI and focuses on protection of the spinal cord and prevention of secondary injury rather than regeneration. InVivo's platform technologies focus on minimizing tissue damage sustained following acute injury and promoting neural plasticity of the spared healthy tissue, which may result in full or partial functional recovery. The technologies encompass multiple strategies involving biomaterials U.S. Food & Drug Administration (FDA) approved drugs, growth factors, and human neural stem cells (hNSCs). InVivo products are biopolymer-based devices that are surgically implanted or injected into the lesion created during traumatic injury, or the 'primary injury'. These scaffolding products protect the damaged spinal cord by mitigating the progression of 'secondary injury' resulting from the body's inflammatory and immune response to injury, and promote neuroplasticity, a process where functional recovery may occur through the rerouting of signaling pathways to the spared healthy issue. Achieving these results is essential to the recovery process, as secondary injury can significantly worsen the immediate damage sustained during trauma. The Company is subject to various laws and regulations relating to safe working conditions, laboratory and manufacturing practices, the experimental use of animals and humans, emissions and wastewater discharges, and the use and disposal of hazardous or potentially hazardous substances used in connection with its research, including infectious disease agents.
» More Articles for NVIV

Headlines

Articles On GuruFocus.com
No related article found.

More From Other Websites
InVivo Therapeutics Appoints Christopher McNulty as Vice President, Business Development & Investor... Jul 01 2014
InVivo Therapeutics to Present at 4th International Neural Regeneration Symposium in China Jun 30 2014
InVivo Therapeutics to Present at 4th International Neural Regeneration Symposium in China Jun 30 2014
InVivo Therapeutics Announces New Responsibilities for Senior Management Team Members Jun 24 2014
INVIVO THERAPEUTICS HOLDINGS CORP. Files SEC form 8-K, Costs Associated with Exit or Disposal... Jun 23 2014
INVIVO THERAPEUTICS HOLDINGS CORP. Files SEC form 8-K, Change in Directors or Principal Officers,... May 30 2014
INVIVO THERAPEUTICS HOLDINGS CORP. Financials May 21 2014
INVIVO THERAPEUTICS HOLDINGS CORP. Files SEC form 8-K, Other Events May 19 2014
InVivo Therapeutics Announces Its Second Clinical Study Site for Neuro-Spinal Scaffold May 14 2014
InVivo Therapeutics Reports 2014 First Quarter Financial Results and Business Update May 12 2014
INVIVO THERAPEUTICS HOLDINGS CORP. Files SEC form 10-Q, Quarterly Report May 12 2014
InVivo Therapeutics Holdings Corp. Closes Public Offering of Common Stock and Warrants May 09 2014
INVIVO THERAPEUTICS HOLDINGS CORP. Files SEC form 8-K, Entry into a Material Definitive Agreement,... May 06 2014
Invivo Therapeutics raises $14M in a common stock and warrant offering May 06 2014
InVivo Therapeutics Holdings Corp. Announces Pricing of Public Offering of Common Stock and Warrants May 06 2014
InVivo Therapeutics Holdings Corp. Announces Proposed Public Offering May 05 2014
INVIVO THERAPEUTICS HOLDINGS CORP. Files SEC form 8-K, Change in Directors or Principal Officers Apr 30 2014
InVivo's Day Has Arrived Apr 30 2014
INVIVO THERAPEUTICS HOLDINGS CORP. Files SEC form 8-K, Regulation FD Disclosure Apr 29 2014
INVIVO THERAPEUTICS HOLDINGS CORP. Files SEC form 8-K, Regulation FD Disclosure Apr 28 2014

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Add Notes, Comments or Ask Questions

User Comments

No comment yet

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK
Email Hide